Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects

Liver International

Volumn 32, Issue 6, 2012, Pages 951-961

  Valle, Adamo ^a,b   Catalán, Victoria ^b,c   Rodríguez, Amaia ^b,c   Rotellar, Fernando ^c   Valentí, Victor ^c   Silva, Camilo ^b,c   Salvador, Javier ^b,c   Frühbeck, Gma ^b,c   Gómez Ambrosi, Javier ^b,c   Roca, Pilar ^a   Oliver, Jordi ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

2 DE; Liver; MALDI TOF; Mass spectrometry; NAFLD; Proteomics; Steatosis; T2DM

Indexed keywords

4 HYDROXYNONENAL; CARBOHYDRATE; CARBONYL DERIVATIVE; GLUTATHIONE; LIVER PROTEIN; METHIONINE; MITOCHONDRIAL ENZYME; PROTEASOME; RETINOIC ACID;

ADULT; ARTICLE; BODY MASS; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; DETOXIFICATION; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPID OXIDATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS;

ADULT; ALDEHYDES; BIOLOGICAL MARKERS; BIOPSY; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FATTY LIVER; FEMALE; GLUTATHIONE; HUMANS; LIVER; METHIONINE; MIDDLE AGED; MITOCHONDRIA, LIVER; OBESITY, MORBID; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEINS; PROTEOMICS; SEVERITY OF ILLNESS INDEX; SPAIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84861987356     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02765.x     Document Type: Article

References (56)

1. Apovian CM. The causes, prevalence, and treatment of obesity revisited in 2009: what have we learned so far? Am J Clin Nutr 2010; 91: 277S-79S.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-41.
3. Chen X, Hess S. Adipose proteome analysis: focus on mediators of insulin resistance. Expert Rev Proteomics 2008; 5: 827-39.
4. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-89.
5. Leite NC, Villela-Nogueira CA, Pannain VL, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011; 31: 700-6.
6. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008; 134: 1369-75.
7. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007; 46: 716-22.
8. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
9. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
10. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
11. Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010; 2010: 837419.
12. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008; 44: 1259-72.
13. Bell LN, Theodorakis JL, Vuppalanchi R, et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010; 51: 111-20.
14. Rodriguez-Suarez E, Duce AM, Caballeria J, et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl 2010; 4: 362-71.
15. Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 2010; 8: 70.
16. Gómez-Ambrosi JSC, Galofré JC, Escalada J, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes 2012; 36: 286-94.
17. Ginde SR, Geliebter A, Rubiano F, et al. Air displacement plethysmography: validation in overweight and obese subjects. Obes Res 2005; 13: 1232-7.
18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
19. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
20. Gomez-Ambrosi J, Fruhbeck G, Martinez JA. Leptin, but not a beta 3-adrenergic agonist, upregulates muscle uncoupling protein-3 messenger RNA expression: short-term thermogenic interactions. Cell Mol Life Sci 1999; 55: 992-7.
21. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
22. Ludwig J, Viggiano TR, Mcgill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
24. Baker MA, Cerniglia GJ, Zaman A. Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem 1990; 190: 360-5.
25. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 68-71.
26. Dey A, Swaminathan K. Hyperglycemia-induced mitochondrial alterations in liver. Life Sci 2010; 87: 197-214.
27. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002; 60: 289-93.
28. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 1992; 54: 885-909.
29. Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J Nutr 2009; 139: 1263S-68S.
30. Zhang L, Perdomo G, Kim DH, et al. Proteomic analysis of fructose-induced fatty liver in hamsters. Metabolism 2008; 57: 1115-24.
31. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1961-71.
32. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-4.
33. Rector RS, Thyfault JP, Uptergrove GM, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010; 52: 727-36.
34. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244-51.
35. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 2005; 25: 760-71.
36. Johnson DT, Harris RA, French S, Aponte A, Balaban RS. Proteomic changes associated with diabetes in the BB-DP rat. Am J Physiol Endocrinol Metab 2009; 296: E422-32.
37. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
38. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-40.
39. Ansorena E, Garcia-Trevijano ER, Martinez-Chantar ML, et al. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 2002; 35: 274-80.
40. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J 2002; 16: 15-26.
41. Santamaria E, Avila MA, Latasa MU, et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003; 100: 3065-70.
42. Avila MA, Berasain C, Torres L, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 2000; 33: 907-14.
43. Varela-Rey M, Martinez-Lopez N, Fernandez-Ramos D, et al. Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide. Hepatology 2010; 52: 105-14.
44. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 1999; 13: 1169-83.
45. Lee JH, Nguyen KH, Mishra S, Nyomba BL. Prohibitin is expressed in pancreatic beta-cells and protects against oxidative and proapoptotic effects of ethanol. FEBS J 2010; 277: 488-500.
46. Cayon A, Crespo J, Guerra AR, Pons-Romero F. [Gene expression in obese patients with non-alcoholic steatohepatitis]. Rev Esp Enferm Dig 2008; 100: 212-8.
47. Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal 2011; 15: 505-21.
48. Morand JP, Macri J, Adeli K. Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia. J Biol Chem 2005; 280: 17626-33.
49. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991; 20: 477-90.
50. Steinberg GR, Kemp BE, Watt MJ. Adipocyte triglyceride lipase expression in human obesity. Am J Physiol Endocrinol Metab 2007; 293: E958-64.
51. Ashla AA, Hoshikawa Y, Tsuchiya H, et al. Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 2010; 40: 594-604.
52. Shiota G. Role of retinoic acid receptor in steatohepatitis-related tumor formation. J Gastroenterol Hepatol 2007; 22(Suppl. 1): S101-7.
53. Gomez-Ambrosi J, Rodriguez A, Catalan V, et al. Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass. Clin Endocrinol (Oxf) 2008; 69: 208-15.
54. Manolescu DC, Sima A, Bhat PV. All-trans retinoic acid lowers serum retinol-binding protein 4 concentrations and increases insulin sensitivity in diabetic mice. J Nutr 2010; 140: 311-6.
55. Cotrim HP, Freitas LA, Alves E, et al. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009; 21: 969-72.
56. Wang XD. Chronic alcohol intake interferes with retinoid metabolism and signaling. Nutr Rev 1999; 57: 51-9.